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Identification of a novel 
inactivating mutation in Isocitrate 
Dehydrogenase 1 (IDH1-R314C)  
in a high grade astrocytoma
Sanne A. M. van Lith1, Anna C. Navis1, Krissie Lenting1, Kiek Verrijp1, Jan T. G. Schepens2, 
Wiljan J. A. J. Hendriks2, Nil A. Schubert1, Hanka Venselaar3, Ron A. Wevers4, Arno van 
Rooij4, Pieter Wesseling1,5, Remco J. Molenaar6, Cornelis J. F. van Noorden6, Stefan Pusch7, 
Bastiaan Tops1 & William P. J. Leenders1
The majority of low-grade and secondary high-grade gliomas carry heterozygous hotspot mutations 
in cytosolic isocitrate dehydrogenase 1 (IDH1) or the mitochondrial variant IDH2. These mutations 
mostly involve Arg132 in IDH1, and Arg172 or Arg140 in IDH2. Whereas IDHs convert isocitrate to alpha-
ketoglutarate (α-KG) with simultaneous reduction of NADP+ to NADPH, these IDH mutants reduce 
α-KG to D-2-hydroxyglutarate (D-2-HG) while oxidizing NADPH. D-2-HG is a proposed oncometabolite, 
acting via competitive inhibition of α-KG-dependent enzymes that are involved in metabolism and 
epigenetic regulation. However, much less is known about the implications of the metabolic stress, 
imposed by decreased α-KG and NADPH production, for tumor biology. We here present a novel 
heterozygous IDH1 mutation, IDH1R314C, which was identified by targeted next generation sequencing 
of a high grade glioma from which a mouse xenograft model and a cell line were generated. IDH1R314C 
lacks isocitrate-to-α-KG conversion activity due to reduced affinity for NADP+, and differs from the 
IDH1R132 mutants in that it does not produce D-2-HG. Because IDH1R314C is defective in producing α-KG 
and NADPH, without concomitant production of the D-2-HG, it represents a valuable tool to study the 
effects of IDH1-dysfunction on cellular metabolism in the absence of this oncometabolite.
Diffuse gliomas are primary tumors of the brain that are thought to develop from (precursors of) astrocytes or 
oligodendrocytes. Based on histopathology and according to WHO guidelines, these cancers are classified as 
grade II-IV astrocytomas or grade II-III oligodendrogliomas1,2. The disease is essentially incurable and median 
overall survival of patients with grade IV astrocytoma (glioblastoma, the most malignant variant) is only 15 
months, despite chemo- and radiotherapy3.
In 2008, somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 were identified in the 
large majority of low grade gliomas and secondary glioblastomas4. These mutations are always heterozygous and 
mostly involve the same amino acid residues; Arg132 in the cytosolic IDH1 and Arg172 or Arg140 in the mito-
chondrial IDH25–7. In glioma, the majority of IDH mutations are found in IDH1, and about 90% are IDH1R132H. 
Extensive research has revealed that these mutations are neomorphic gain-of-function mutations, resulting in 
the conversion of α -ketoglutarate (α -KG), the normal product of IDH-mediated decarboxylation of isocitrate, to 
D-2-hydroxyglutarate (D-2-HG) which can accumulate to millimolar concentrations8. During the conversion of 
α -KG to D-2-HG by the mutant enzyme, NADPH is oxidized.
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Because of the molecular similarity between α -KG and D-2-HG, the latter can competitively inhibit the 
activity of a range of α -KG-dependent dioxygenases, of which over 60 have been identified9,10. Most important 
examples are the Ten-Eleven-Translocation 2 (TET2) DNA demethylases (resulting in the CpG-island hyper-
methylator phenotype in IDHMUT cells) and Jumonji-C (JMJC) histone demethylases (resulting in histone hyper-
methylation)11–13. The net result is a transcriptional profile that contributes to tumorigenesis via mechanisms that 
are still poorly understood. Although this has been matter of debate, consensus is now that D-2-HG can promote 
degradation of the transcription factor hypoxia-inducible factor (HIF-1α ), possibly after non-enzymatic oxida-
tion to α -KG14. How this exactly contributes to oncogenesis is still an active field of investigation15–17.
The effects of expression of IDH1-mutants and/or D-2-HG on tumor metabolism have started to receive 
attention now18. It was recently shown that D-2-HG inhibits the tricarboxylic acid (TCA) cycle enzyme succinate 
dehydrogenase, possibly leading to hypersuccinylation of proteins and anti-apoptotic effects19. Because mutant 
IDH1 lacks isocitrate-to-α -KG conversion activity, normally a predominant source of cytosolic NADPH in the 
brain20, IDHMUT cells are predicted to have lower steady state levels of NADPH, an effect that will be augmented 
by NADPH-oxidation during D-2-HG production. Thus, IDH mutations impact the redox status of glioma cells.
Additionally, IDH mutations may affect anabolic pathways: IDH1/2 can reduce α -KG back to isocitrate which 
may serve as carbon source for fatty acid and lipid synthesis via citrate and acetyl-CoA21,22 but IDH1R132H lacks 
this reverse activity23. It is conceivable therefore, that IDHMUT tumors need metabolic salvage pathways to allow 
tumor progression and this is supported by the finding of relatively normal α -KG levels in a patient-derived 
orthotopic IDH1R132H oligodendroglioma model24. Because IDH1MUT cells display higher sensitivity to glutami-
nase inhibitors than IDHWT cells25, glutamine has been proposed to feed in into the mitochondrial TCA cycle as 
an anaplerotic source of α -KG, via the activities of glutaminase and glutamate dehydrogenase (GDH). We previ-
ously postulated that gliomas may resort to direct import of glutamate, a ubiquitous neurotransmitter in brain, 
to allow GDH-mediated α -KG production26,27. NADH/NADPH, generated during this reaction would simul-
taneously supplement the NAD(P)H pool. These metabolic changes could all play a role in tumor cell mainte-
nance and therefore be an Achilles heel and target for therapeutic inhibition. However, uncoupling the metabolic 
alterations that result from NADPH/α -KG depletion from the pleiotrophic effects of D-2-HG is a difficult task.
In this study we describe a novel heterozygous IDH1 mutation which we uncovered by next generation 
sequencing of a glioblastoma from which a patient-derived xenograft model and corresponding cell line were 
generated. We show that this IDH1R314C mutant does not convert isocitrate to α -KG, unless at non-physiological 
concentrations of NADP+, and does not produce D-2-HG. These properties make that IDH1R314C tumor models 
are valuable tools to study the relevance of α -KG/NADPH depletion versus D-2-HG formation in gliomagenesis 
and tumor progression.
Results
E98 cells contain a rare heterozygous IDH1R314C mutation located in the NADP+ binding 
pocket. The patient-derived E98 astrocytoma model carries a number of glioma-typical genetic mutations 
and is phenotypically similar to clinical glioma when grown as orthotopic xenografts28–30. This makes this model 
of high interest as a prototypical glioblastoma model for testing of targeted therapeutics31–34. Because the design of 
rational targeted therapies requires a detailed analysis of genetic aberrations, we subjected this cell line to targeted 
genomic next generation sequencing via Ion Torrent analysis using a primer set that allows parallel deep sequenc-
ing of 409 genes with known involvement in cancer-related pathways. As we unfortunately did not have access 
to blood of the E98 donor, SNPs and variants with mean allelic frequency (MAF) > 1% were filtered out using 
sequence data from pooled blood samples as reference. Due to our general interest in IDH1, our attention was 
specifically drawn to a heterozygous C to T mutation at position 940 in the IDH1 gene (Fig. 1A) which results in 
the p.Arg314Cys substitution. Presence of this mutation was verified in the original patient material (Fig. 1B). To 
check for the incidence of this mutation, 103 DNA samples from glioma (see Supplementary Table 1) were Sanger 
sequenced. None of these samples contained the p.R314 mutation. Data mining of the Exome Sequencing Project 
(ESP) database (www.exac.broadinstitute.org/) revealed that this variant has not been identified in 121,410 alleles. 
Mining of the Cosmic database revealed only one reported IDH1 c.941G> A/p.R314H mutation in a gastric car-
cinoma (mutation ID COSM4090677). Thus, the R314C mutation is a rare mutation.
Since Arg314 is located in the NADP+ binding pocket35 we studied the experimentally solved structure of 
IDH1WT and IDH1R314C in complex with NADP+ using YASARA. As shown in Fig. 1C, the R314C mutation sig-
nificantly alters the tertiary structure resulting in an imperfect fit of NADP+ in the binding pocket, mainly due to 
the lack of interaction between the negatively charged 2′ -phosphate of the co-enzyme NADP+ and the positively 
charged amine group of the arginine, and lack of ionic interactions between the Arg314 and glutamate residues 
on position 247 and 253 in the other subunit.
IDH1R314C is defective in isocitrate to α-KG conversion. We first examined the activity of puri-
fied IDH1R314C-GST proteins, using IDH1WT-GST and IDH1R132H-GST as positive and negative controls. All 
enzymes could be readily produced and purified (Fig. 2A). Under the conditions tested, both IDH1R132H-GST and 
IDH1R314C-GST did not show isocitrate-to-α -KG conversion activity whereas IDH1WT-GST did (Fig. 2B). The 
absence of α -KG formation by IDH1R132H-GST and IDH1R314C was confirmed with LC-MS (Fig. 2C). Importantly, 
whereas IDH1R132H-GST was active in converting α -KG to D-2-HG (as revealed by oxidation of NADPH) the 
IDH1R314C-GST mutant was completely devoid of this activity (Fig. 2D). Thus, IDH1R314C homodimers are inac-
tive in converting isocitrate and NADP+ to α -KG and NADPH and, unlike IDH1R132H-GST, do not consume 
NADPH, consistent with the lack of D-2-HG production by E98 xenografts that has already been described 
before36.
The IDH1R132 mutation in human gliomas always occurs in a heterozygous manner, resulting in a theoretical 
1:2:1 distribution of IDHWT/WT, IDHWT/MUT and IDHMUT/MUT dimers. This stoichiometry may be important for 
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balanced IDH activity, because D-2-HG can only be formed via an intimate crosstalk between wild-type and 
mutant subunits, for which α -KG is a product and substrate, respectively. To analyze the effects of IDH1R314C 
overexpression in eukaryotic cells we performed enzymatic assays with cell extracts from HEK293T cells, tran-
siently overexpressing IDH1WT, IDH1R132H or IDH1R314C as well as lentivirally transduced LN229 and U251 gli-
oma cells, stably expressing the different IDH1 mutants (Fig. 3A). To be able to distinguish recombinant from 
endogenous IDHWT and allow statements on IDHWT/MUT ratios we equipped the mutated reading frames with 
a BAPHIS (biotin-acceptor peptide-8xHis) tag, increasing molecular weight with ~3 kDa. Intriguingly, irre-
spective of the method of genetic modification (transfection or lentiviral transduction) expression levels of 
recombinant enzymes were lower than that of the endogenous enzymes, with IDHR132H consistently being low-
est, possibly a result of negative selection for IDH1R132H-BAPHIS overexpression and associated toxic levels of 
D-2-HG37. Consistent with the absence of activity of purified IDH1R314C homodimers (Fig. 2B), for all cell lines 
NADP+-dependent oxidative decarboxylation of isocitrate was significantly lower in IDH1R314C-BAPHIS express-
ing cells than in IDH1WT-BAPHIS cells (Fig. 3B). Of note, the reduced activity of IDH1R314C-BAPHIS in U251 
cell extracts could be rescued by performing the enzymatic assay in supraphysiological concentrations of NADP+ 
(Supplementary Figure 1), in line with loss of NADP+-affinity as predicted from the solved structure in Yasara, 
and as described earlier by Lee et al.35. Consistent with this model, the R314C mutation caused an eight-fold 
increase in Km for NADP+ (318 μ M vs 38 μ M for IDHWT, Fig. 3C). This predicts that IDH1R314C is inactive under 
physiological NADP+ concentrations. Of note, activity of GST-IDH1R314C homodimers at higher concentrations 
of NADP+ was too low to calculate Km for isocitrate.
Figure 1. Identification of IDH1R314C in a high grade astrocytoma. (A) Sequencing trace showing the 
heterozygous C to T mutation at position 940 in the IDH1 gene found in the E98 cell line and (B) primary 
tumor material. This mutation leads to the p.Arg314Cys substitution in the IDH1 protein. (C) Display of the 
3D- structure of human IDH1R314C generated with YASARA (PDB-file 3inm). The IDH1WT homodimer is 
displayed with bound cofactor NADP+ (yellow), and the arginine residue on position 314 (red), both subunits 
are coloured in a different shade of grey. The inset shows the mutated cysteine (red) superimposed on the 
original arginine (green).
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As expected from the lack of NADPH consumption when incubated with α -KG (Fig. 2D), IDH1R314C-BAPHIS 
expressing LN229 and U251 glioblastoma cell lines did not produce 2-HG, in contrast to their IDH1R132H-BAPHIS 
counterparts (Fig. 3D).
Discussion
Since their discovery, hotspot mutations in IDH enzymes have become a major focus of research. The oncogenic 
potential of IDH1R132H has been attributed to epigenetic alterations, resulting from the production of the alleged 
oncometabolite D-2-HG9,10,38. Furthermore it has been shown that proliferation of IDH1R132H cells requires met-
abolic rescue programs that depend on in vivo tumor-stroma interactions, possibly involving glutamate import26.
We here identify and characterize IDH1R314C, a novel and rare mutation in IDH1 in a high grade astrocytoma 
which has not been reported before. We show that IDH1R314C has a greatly reduced affinity for NADP+, in agree-
ment with a previous structure-function relationship study on porcine IDH135 and is consequently defective 
in oxidizing isocitrate to α -KG. The R314C mutation did not shift the cofactor dependency from NADP+ to 
NAD+ (Supplementary Figure 2) as was previously reported for mutated IDH1 from the halobacterium Haloferax 
Volcanii39.
To define an exact role for IDH1R314C in tumor formation and biological behavior of cancer cells is impossible 
in the context of the many more mutations that are found in E9840. To study this further, isogenic E98 cell lines 
with a repaired IDH1R314R allele are required and such technically challenging cell lines are not yet available.
The decreased potential of IDH1R314C cells to produce α -KG and NADPH in the cytosol may directly impact 
on redox potential, lipid synthesis and membrane production and may explain the slow growth rates of E98 cells 
in vitro (doubling time of 46 hrs, data not shown). Interestingly, despite these very slow growth rates, in vivo E98 
xenografts represent the most aggressive diffuse infiltrative brain tumor model in our lab, killing mice within 4–5 
weeks after intracerebral implantation28. This illustrates that the brain micro-environment is crucially involved in 
allowing growth of E98 cells. Since the redox status of cells may particularly impact on cell migration41 it would 
be of high interest to investigate how relatively low NADPH/NADP+ ratios in E98 cells in vivo are associated 
with active cell migration, leading to the diffuse infiltrative phenotype. Further unraveling of the specific in vivo 
metabolic salvage pathways that are adapted by E98 cells and may be involved in its aggressive behavior may lead 
to potential novel ways for therapeutic intervention.
In oncology, most NGS protocols aim for detection of actionable hot spot mutations in known genes only, 
leaving a potentially huge amount of mutations with significance for tumor biology, undetected and this is the 
reason why we only now recognized that E98 cells carry the IDH1R314C mutation24. Alterations in genes encoding 
metabolic enzymes may be directly or indirectly involved in tumorigenesis based on subtle distortions in equilib-
ria between metabolic intermediates and/or oxidative milieu.
In conclusion, we identified a novel IDH1R314C mutant that shares with the common IDH1R132H mutant a 
defect in isocitrate-to-α -KG conversion activity, but lacks the capacity to produce D-2-HG. Future comparative 
Figure 2. Homodimeric IDH1R314C-GST is defective in the isocitrate-to α-KG reaction and does not produce 
D-2-HG. (A) SDS-page gel stained with coomassie brilliant blue showing expression of purified IDH1-GST 
constructs. (B) Fluorescent monitoring of NADPH formation at 340 nm shows that only purified IDH1WT-GST 
is capable to convert isocitrate to α -KG under the reaction conditions tested, whereas IDH1R132H-GST and 
IDH1R314C-GST are inactive. (C) α -KG production by IDH1-GST enzymes was measured with LC-MS. Note 
that only IDH1WT-GST is capable of isocitrate-to-α -KG conversion. (n.d. = non detectable, area < 150).  
(D) Fluorescent monitoring of NADPH reduction shows that only purified IDH1R132H-GST is active in the  
α -KG-to-D-2-HG conversion. Both IDH1WT-GST and IDH1R314C-GST lack the capability to produce D-2-HG.
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profiling studies using isogenic cell lines expressing IDHWT, IDH1R132H or IDH1R314C will allow us to distinguish 
between epigenetic and metabolic alterations, resulting from NADPH/α -KG depletion or D-2-HG accumulation.
Methods
E98. Generation of the E98 model which was derived from a grade IV astrocytoma, was described before28. All 
animal experimental work was performed in accordance with the guidelines of and was approved by the local eth-
ical committee for animal experimentation of Radboud University. An adherent E98 cell line was generated from 
mouse xenografts via routine procedures29,40 and cultured in DMEM (Lonza, Basel, Switzerland) supplemented 
with 10% FCS (Gibco, ThermoFisher Scientific, Watlham, MA, USA) and 40 μ g/ml gentamycin (Centrafarm, 
Etten-Leur The Netherlands).
Next generation sequencing. Genomic DNA from E98 cells and from original tumor material was ana-
lyzed by semi-conductor sequencing (IonPGM, Life Technologies, ThermoFisher Scientific, Watlham, MA, USA) 
using the comprehensive cancer panel (Life Technologies, ThermoFisher Scientific, Waltham, MA, USA) detect-
ing copy number variations and mutations in 409 cancer-related genes. An IonPGM E98 library was generated 
according to the manufacturer’s protocol. In short, 10 ng of DNA per pool was amplified in 21 cycles by PCR 
using the Ion AmpliSeqTM mastermix, followed by barcode and adapter ligation. Amplified products were puri-
fied with Agencourt AMPure XP beads (Beckman Coulter Genomics, High Wycombe, UK). The library was 
diluted to 20 pM and emulsion PCR was performed using the Ion OneTouchTM 200 Template kit following the 
manufacturer’s protocol. Next, Ion Sphere Particles (ISPs) were recovered and enriched for template positive 
ISPs using Dynabeads MyOne Streptavidin C1 beads (Life Technologies, ThermoFisher Scientific, Waltham, MA, 
USA) in the Ion OneTouchTM ES instrument (Life Technologies, ThermoFisher Scientific, Waltham, MA USA). 
ISP enrichment was quantified using the Qubit 2.0 fluorometer (Life Technologies, ThermoFisher Scientific, MA, 
Figure 3. IDH1R314C-BAPHIS expression in glioma cell lines leads to reduced forward activity compared 
to IDHWT expression. (A) Western blots showing expression of IDH1-BAPHIS in transiently transfected 
HEK293t and lentivirally transduced LN229 and U251 glioma cells. Blots were stained with anti-IDH1PAN and 
anti-IDH1R132H as indicated, or with anti-GAPDH as a loading control. Since the recombinant proteins are 
~3 kDa larger than endogenous IDH1 they can be distinguished from the endogenous IDH1. Control LN229 
and U251 were transduced with empty vector virus (EV). (B) Monitoring of NADPH formation after isocitrate/
NADP+ addition to extracts from transfected/transduced cell lines. NADPH formation was monitored 
by absorbance measurements at 340 nm. Note that IDH1R314C-BAPHIS was far less effective in oxidative 
carboxylation of isocitrate than IDH1WT-BAPHIS. (C) Km values of IDH1-GST for NADP+. The Km value for 
NADP+ for IDH1R132H-GST could not be determined. (D) D-2-HG production by IDH1-BAPHIS expressing 
cell lines was measured with LC-MS. Only IDH1R132H-BAPHIS expressing cells were capable of D-2-HG 
production.
www.nature.com/scientificreports/
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USA). Sequencing primer and polymerase were added to the final enriched spheres before loading onto an Ion 
318 chip according to the Ion PGMTM 200 sequencing kit protocol. Variants were called using NextGene (JSI) 
and filtered for common variants (MAF > 1%) in the general population.
Visualization of IDH1 structure with YASARA. The structure of human IDH1 has been experimentally 
solved and can be found in PDB-file 3inm8. We used the WHAT IF & YASARA twinset for visualization and 
analysis42,43.
PCR and cloning of IDH1 constructs. Total RNA was isolated from cell lines using TRIzol reagent 
(Life Technologies, ThermoFisher Scientific, Waltham, MA, USA) and converted to cDNA using oligo-dT and 
MMLV reverse transcriptase (New England Biolabs, Ipswich, MA, USA) using standard protocols. Open reading 
frames for IDH1WT, IDH1R132H and IDH1R314C were PCR amplified from HT29, E478 and E98 cDNA, respec-
tively, using primers IDH-EcoRIFw [5′ -CGAATTCACTGTCAAGGTTTATTGAAGTC-3′ ] and IDH-AgeIRev 
[5′ -CACCGGTAAGTTTGGCCTGAGCTAG-3′ ] and Phusion DNA polymerase (Finnzymes, ThermoFisher 
Scientific, Watlham, MA, USA). PCR products were digested with EcoRI and AgeI (New England Biolabs, 
Ipswich, MA, USA) and cloned in fusion to a C-terminal biotin-acceptor peptide (BAP) and an 8xhis tag (HIS) 
in vector PHLsec-BAPHIS AgeI/EcoRI, derived from PHLsec-HIS (Addgene, Cambridge, MA, USA) using T4 
DNA ligase (New England Biolabs, Ipswich, MA, USA). The BAPHIS tags were added to distinguish recombinant 
from endogenous IDH by molecular weight and to allow Ni-bead purification. Clones containing the respective 
mutations were selected via Sanger sequencing. For generation of lentiviral constructs, the different ORFs were 
recloned in vector pENTRY which was recombined with pLENTI using the GATEWAY system via standard 
procedures.
In parallel, IDH ORFs were cloned in fusion with GST in E. coli expression vector pDEST15 as described 
before37.
GST fusion protein expression and purification. GST fusion proteins were expressed in E. coli strain 
ER2566 via standard induction protocols. Briefly, 2xTY medium supplemented with 50 μ g/ml ampicillin (Roche, 
Basel, Switzerland) was inoculated with 1% v/v overnight culture. Protein expression was induced with 1 mM 
IPTG (Serva, Heidelberg, Germany) at OD600~0.6. After 3 hours at 30 °C, bacteria were harvested by centrif-
ugation and resuspended in 300 mM NaCl, 50 mM TRIS/HCL pH 8.0 supplemented with Complete protease 
inhibitor (Roche, Basel, Switzerland). Cells were lysed by 3 freeze-thaw cycles, followed by sonication (4 × 15 sec-
onds, 25% amplitude, Bioruptor, Diagenode) and centrifugation (3500 rpm, 20 min). Proteins were purified using 
glutathione beads (Pierce, ThermoFisher Scientific, Waltham, MA, USA), eluted with 10 mM glutathione and 
dialyzed extensively against 150 mM NaCl, 25 mM TRIS/HCL pH 7.5. Expression and purity were checked by 
SDS-PAGE gel electrophoresis and Coommassie Brilliant Blue staining.
Transient transfection experiments. HEK293T cells were grown to 30% confluence in 6 wells 
plates in DMEM supplemented with 10% FCS and 40 μ g/ml gentamycin. Cells were transfected with 2 μ g 
pHLsec-IDH1MUT-BAPHIS, IDH1WT-BAPHIS or pIRESneo-EGFP using Fugene HD reagent according to the 
manufacturers’ protocol (Roche, Basel, Switzerland). After 2 days, cells were harvested and processed to cell lysates 
by scraping in 150 μ l sucrose buffer (0.32 M sucrose in 10 mM TRIS-HCL pH 7.5) and sonicating on ice (3 cycles 
of 30 sec max power and 30 sec off in Bioruptor, Diagenode). Lysates were centrifuged (14000 rpm, 10 min, 4 °C) 
and supernatants were subjected to BCA assays (Pierce, ThermoFisher Scientific, Waltham, MA, USA) for protein 
concentration measurements and stored at − 20 °C until further analysis. To quantify IDH1 protein expression, 
20 μ g of total cytosolic protein was subjected to 10% SDS-PAGE and electroblotted onto a nitrocellulose mem-
brane (Whatman Optitran BA-S85, GE healthcare, Little Chalfont, UK). After blocking in Odyssey Blocking 
buffer (LI-COR biosciences, Licoln, NE, USA) in PBS (1:1) the membrane was incubated with rabbit-anti-IDH1 
(1:1000, HPA035248, Sigma-Aldrich, St. Louis, MO, USA) and mouse-anti-IDH1R132H (1:400, H09L, Dianova, 
Hamburg, Germany) in blocking buffer, followed by incubation with goat-anti-mouseDyLight800 (1:10.000, 
ThermoFisher Scientific, Waltham, MA USA) or goat-anti-rabbitAlexa680 (1:10.000, Invitrogen, ThermoFisher 
Scientific, Waltham, MA, USA). After washing, blots were analyzed on the Odyssey scanner (LI-COR biotech-
nology, Lincoln, NE, USA).
Generation of stable IDH1MUT overexpression glioma cell lines. LN229 and U251 cells were trans-
duced with lentiviral vectors encoding IDH1WT-BAPHIS, IDH1R132H-BAPHIS, IDH1R314C-BAPHIS or an empty 
vector (EV) control as described before44. Transduced cells were selected using blasticidin and cultured in DMEM 
supplemented with 10% FCS and 40 μ g/ml gentamycin. Cells were grown to 80% confluency in 10 cm ø culture 
plates (Corning, Corning, NY, USA). Cell culture media were collected and stored at − 20 °C until later analysis. 
Cells were collected and cytosolic extracts were prepared in 400 μ l sucrosebuffer as described before. Twenty μ g of 
protein was subjected to SDS-PAGE gel electrophoresis and western blot to quantify protein expression.
IDH activity measurements. Isocitrate-to-α -KG and α -KG-to-2-HG conversion rates of the purified 
IDH1-GST enzymes were determined by monitoring NADPH generation over time. Assays were performed in 
100 μ l freshly prepared assay solution (2 mM MgCl2 in 100 mM TRIS/HCL pH 7.4) containing 10 mM NADP+ 
(Sigma-Aldrich, St. Louis, MO, USA) and 10 mM isocitrate (Sigma-Aldrich, St. Louis, MO, USA) (forward assay) 
or 10 mM NADPH (Sigma-Aldrich, St. Louis, MO, USA) and 10 mM α -KG (Sigma-Aldrich, St. Louis, MO, USA) 
(reverse assay). Four μ g of purified IDH1-GST fusion proteins were incubated with assay solution in a 96 wells 
plate at 37 °C (BD Falcon, Franklin Lakes, USA) and fluorescence (Ex. 340 + /− 10 nm, Em. 440 + /− 10 nm), 
was measured every 15 seconds over a period of 5 minutes with an Omega FluoStar (BMG Labtech, Ortenberg, 
Germany). To examine enzyme kinetics in more detail, 4 μ g of IDH1-GST proteins were incubated with varying 
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NADP+ concentrations (0–500 μ M) and 100 μ M isocitrate at 22 °C. Absorbance at 340 nm was measured every 
20 seconds with a Benchmark Plus Microplate Spectrophotometer (Bio-Rad, Hercules, CA, USA). Non-linear 
regression analysis (Michaelis-Menten) was performed in Graphpad Prism 5.03.
To determine NAD+ dependency, 4 μ g of IDH1-GST proteins were incubated with 100 μ l assay solution con-
taining 2 mM MgCl2, 500 μ M isocitrate and 2, 5 mM NAD+ (Sigma-Aldrich, St. Louis, MO, USA) in 100 mM 
TRIS-HCL pH 7.4 at 22 °C. A sucrose extract made from human liver was taken as a control. Absorbance at 
340 nm was monitored as described.
For enzyme measurements in extracts of eukaryotic cells, 50 μ g of total cytosolic protein were incubated with 
assay solution (2 mM MgCl2, 500 μ M isocitrate in 100 mM TRIS/HCL pH 7.4) containing 100 μ M NADP+ in 96 
wells plates (Greiner) at 22 °C and NADPH generation was quantified as described before.
D-2-HG, α-KG and isocitrate measurements by isotope dilution LC-MS. D-2-HG levels in cell 
culture media were measured using stable isotope dilution liquid chromatography tandem mass spectrometry 
(LC-MS) as described before36.
α -KG and isocitrate levels were determined in in vitro IDH1 reaction mixtures. 4 μ g of IDH1-GST proteins 
were incubated in 150 μ l freshly prepared assay solution (2 mM MgCl2 in 100 mM TRIS/HCL pH 7.4) containing 
500 μ M isocitrate and 100 μ M NADP+. After 20 min incubation at 22 °C the reaction was stopped using 20 μ l 4% 
HCOOH. 25 μ l of this solution was mixed with 25 μ l 9 μ M 13C5-2-HG stable isotope (Chiralex, Nijmegen, The 
Netherlands) in deionized water and 75 μ l deionized water before passing it through an Amicon Ultra 30 kDa 
Centrifugal Filter (Merck Millipore, Billerica, MA, USA) by centrifugation (14000 g, 30 min). 2 μ l of the filtrate 
was injected onto a Atlantis T3 HPLC Column (2.1* 100 mM dp 3 μ ) and run with 12.5% MeOH in 87.5% 0.3% 
HCOOH in water. The column was connected to a Waters Quattro Premier tandem mass spectrometry fitted with 
an ESI probe operated in negative mode, recording the following MRM transitions, as summarized in Table 1.
Statistics. All experiments were performed in triplicate. Data were processed in Excell (Microsoft, Redmond, 
WA, USA) and enzyme kinetics were determined by fitting of Michaelis Menten in Graphpad Prism 5.03 
(Graphpad Software, La Jolla, CA, USA).
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